Sichenzia Ross Friedman Ference LLP Represents Aridis Pharmaceuticals in $15 Million Private Placement
PRESS RELEASE – New York, NY – August 25, 2016 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the firm has represented Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, in a private placement of preferred stock and warrants resulting in total gross proceeds of $15,216,241.
Maxim Merchant Capital, a division of Maxim Group LLC, acted as the exclusive placement agent for the offering. The Sichenzia Ross Friedman Ference LLP team was led by Partner Jeff Fessler, Avital Even-Shoshan, Evan Berger and Nazia Khan.
Visit SRFK's LinkedIn page
Latest posts by Sichenzia Ross Ference Kesner LLP (see all)
- Founding Partner Marc Ross Speaks at Benzinga Cannabis Capital Conference - August 15, 2018
- Founding Partner Gregory Sichenzia Featured in the Media Discussing Scrutiny of Elon Musk’s Twitter Communications - August 15, 2018
- Founding Partner Gregory Sichenzia Featured on Business Insider Discussing Elon Musk’s Tweets and Securities Legality - August 8, 2018